Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84), published as a clinical trial.

In primary hyperparathyroidism, adenoma size is a major determinant of disease severity and manner of presentation, but the reason for the large variation in size (>100-fold) is unknown.

One factor could be the level of vitamin D nutrition, because in India, where vitamin D deficiency is endemic, adenomas are larger and the disease more severe than in the U.S.

Who Took Part

The abstract describes 51 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

What Was Measured

In primary hyperparathyroidism, adenoma size is a major determinant of disease severity and manner of presentation, but the reason for the large variation in size (>100-fold) is unknown.

One factor could be the level of vitamin D nutrition, because in India, where vitamin D deficiency is endemic, adenomas are larger and the disease more severe than in the U.S.

Topics PubMed links to this paper include Adenoma, Calcitriol, Hormone Replacement Therapy, Hyperparathyroidism, Hypocalcemia, Nutritional Status and Organ Size.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in 51 patients.

The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.